Brainstorm Cell Therapeutics Inc. (BCLI)

0,4560 -0,0110 (-2,36%) Al cierre: 04:00PM EDT

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas
28th Floor
New York, NY 10019
United States
201 488 0460
https://www.brainstorm-cell.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 29

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Chaim Lebovits	President & Co-CEO	878,78k	N/A	1971
Dr. Irit Arbel DSc, Ph.D.	Co-Founder & Independent Vice Chair of the Board	N/A	N/A	1960
Ms. Alla Patlis CPA, M.B.A.	Interim CFO & Controller	130,92k	N/A	1987
Mr. Uri Yablonka	Executive VP, Chief Business Officer, Secretary & Director	247,06k	N/A	1977
Dr. Daniel Offen Ph.D.	Chief Scientific Advisor	N/A	N/A	N/A
Ms. Mary Kay Turner	Senior Vice President of Patient Advocacy & Government Affairs	N/A	N/A	N/A
Dr. Ibrahim Dagher M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1969

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Gobierno corporativo

El ISS Governance QualityScore de Brainstorm Cell Therapeutics Inc., a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 9; Tablero: 3; Derechos de los accionistas: 2; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.